Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
10.69
+0.61 (6.05%)
At close: Mar 31, 2026, 4:00 PM EDT
10.51
-0.18 (-1.68%)
After-hours: Mar 31, 2026, 7:36 PM EDT
Elicio Therapeutics Employees
Elicio Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
n/a
Profits / Employee
-$1,199,121
Market Cap
196.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | 1 | 3.13% |
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Tonix Pharmaceuticals Holding | 142 |
| Adagene | 138 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Caribou Biosciences | 97 |
| Keros Therapeutics | 78 |
| Compugen | 75 |
ELTX News
- 14 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 19 days ago - Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 months ago - Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent - Seeking Alpha
- 5 months ago - Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC - GlobeNewsWire